Viking Therapeutics (VKTX) released new clinical trial data on Sunday ... In a phase 2 trial of the same drug ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and ... again be in focus when Novo reports results for its diabetes drug Ozempic and ...
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...